SOPH Chief Scientific Officer Xu Zhenyu Sells $29K of Stock

Xu Zhenyu, Chief Scientific Officer of SOPHiA GENETICS SA (NASDAQ: SOPH), sold 4,000 shares on October 13, 2026, for about $28,727, at an average price of $7.18 each. This planned sale comes as the stock traded at $6.81 on the NasdaqGS following its recent close of $8.19.

Zhenyu's sale adds to a series of insider transactions at SOPHiA GENETICS. Most recently, Jurgi Camblong, the company's CEO, sold shares on June 25 and June 26, totaling $108,756 in value, while also making a notable purchase of 31,940 shares on the latter date.

Other Institutional Activity in SOPHiA GENETICS

Generation Investment Management LLP holds 6,789,560 shares of SOPHiA GENETICS, with a value of about $46.4 million. AIGH Capital Management LLC increased its stake by 1,977,097 shares, bringing its total to 3,954,194 shares valued at approximately $27 million. Akre Capital Management, LLC remains steady with 3,719,140 shares valued at about $25.4 million. Royce & Associates LP saw an increase of 1,565,454 shares, ending with 3,381,736 shares worth roughly $23.1 million. Principal Financial Group, Inc. also grew its holdings by 955,031 shares, totaling 2,364,256 shares valued at about $16.2 million.

SOPHiA GENETICS SA Stock Down 6.6%

The stock of SOPHiA GENETICS currently trades at $6.81, significantly lower than its 52-week high of $8.98. This recent sale by Zhenyu occurs as the stock is near its 50-day moving average of $7.28, indicating some volatility in its performance.

Recent Earnings

In its latest earnings report, SOPHiA GENETICS reported revenue of $86.2 million, reflecting a growth of 27.2%. However, the company has not turned a profit, with an EPS of -$1.16. Investors will be watching closely for the next earnings date on November 3, 2026.

Insider Buying and Selling at SOPHiA GENETICS SA

Recently, Jurgi Camblong sold 1,373 shares on June 25, 2026, at an average price of $5.70, totaling about $7,826. Camblong also sold 31,940 shares on June 26, 2026, without a recorded price, while he bought back 31,940 shares at $3.16, worth about $100,930. Additionally, Chief Technology Officer Abhimanyu Verma sold 6,944 shares on the same day, valued at approximately $38,261.

Analysts Set New Price Targets

On October 12, 2026, HC Wainwright & Co. reiterated a Buy rating on SOPHiA GENETICS, maintaining a price target of $14.0, which was previously set at $12.0. BTIG also maintains a Buy rating with a price target of $9.0, raised from $8.0 on August 5. The consensus target among analysts stands at $9.75, reflecting four opinions.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a healthcare company based in Rolle, Switzerland. It develops cloud-based software technologies that analyze healthcare data to provide insights for diagnostic and treatment purposes. The recent insider trading activity may reflect varying levels of confidence in the company as it navigates its growth trajectory.

Bottom Line

Investors should keep an eye on upcoming earnings slated for November 3, 2026, as well as future insider transactions. Zhenyu's recent sale is part of a broader trend of insider trading at SOPHiA GENETICS, reflecting ongoing developments within the company. Note that this insider transaction is based on prior disclosures, and the information may not reflect the current position of the insiders.